It's official big Pete is on island and he has with him a " portable air conditioner " This man does not travel small-- must find him. Is the ice cube one of mans ten great inventions? YES. The first marketed soft drinks appeared in the 17th century asa mixture of water and lemon juice sweetened with honey. In 1676 the Compagnie de Limonadiers was formed in Paris and granted a monopoly for the sale of its products. Vendors carried tanks on their backs from which they dispensed cups of lemonade. Who invented cool drinks? Within a decade of the invention of carbonated water by Joseph Priestley in 1767 inventors in Britain and in Europe had used his concept to produce the drink in greater quantities, with one such inventor, J. J. Schweppe, forming Schweppes in 1783 and selling the world's first bottled soft drink. (Also in the 19th century, Chilean brewers were using ice from icebergs to refrigerate their beer. By the 1850s, harvesting glacial ice became the go-to method for beer refrigeration. Ships towed icebergs from as far as the South Pole.) The rest of Europe scoffed at this use of ice to cool drinks, seeing it as “a mark of excessive and effeminate luxury.” (Ice and Refrigeration Illustrated, July 1901, p.6) They went from scoffing to partaking, adding ice to every drink they could. While ice has remained popular in America, the biggest modern change to its preparation comes from Japan, where there has been a longstanding reverence for ice. That inspired the veneration with which ice is treated in Japanese cocktail culture, in turn influencing a generation of bartenders around the world to start taking ice more seriously. This is why you’ll see bartenders emulating the likes of famed Japanese mixologist Hidetsugu Ueno, who, at Bar High Five in Tokyo, uses a blade to carve ice into “jewels.” His work and others’ has inspired bartenders around the world to consider ice’s precise shapeandclaritywhen preparing cocktails.
Yum! looks like a good bet as restaurant stocks come back to life, Barron's says 09:30 YUM While the fundamentals look lousy, restaurant stocks have begun showing signs of life, Ben Levisohn writes in this week's edition of Barron's. And in an environment of slowing growth, Yum! Brands (YUM) looks particularly attractive, the author notes. The owner of Kentucky Fried Chicken and Taco Bell offers cheaper food for consumers who may be looking to trade down, while also growing at a relatively fast clip. It could also get a boost from China, which is trying to reboot its economy following multiple COVID lockdowns, the publication adds.
wow the great VICR exploded up Fri- Vicor Corporation (VICR) NasdaqGS - NasdaqGS Real Time Price. 65.02+9.20 (+16.48%) At close: July 22 04:00PM EDT
Why does man challenge the sea? He has since time immortal- My wife and son and others battled the big waves and cooled off as I watched like a leper from the sidelines. I've got to get in that water!
My son is into sharks and he has an app that tracks tagged sharks in our area-- there's a great white right out there! I see his blip on the screen and it's a couple tail wags away.
The slide in RBOB gasoline, and concerns around gasoline demand destruction, also adds to pressure on crude oil, because "if refiners don't need to make gasoline, then they don't need feedstock crude oil to make gasoline," Mizuho Securities' Robert Yawger said. But despite troubling signs for crude demand, "the oil market remains very tight and is not allowing WTI crude to break below the mid-US$90s," according to Oanda's Ed Moya. Front-month Nymex crude (CL1:COM) for September delivery ended the week +0.1% to $94.70/bbl, its lowest settlement value since April 11, while September Brent crude (CO1:COM) closed +2% for the week at $103.20/bbl. Meanwhile, Henry Hub natural gas futures (NG1:COM) soared 18.3% for the week to $8.299/MMBtu, as some of the hottest weather on record in the U.S. and Europe helped demand.
looking at 2 best ideas of UBS & Credit Suisse coverage- -> Sales + 9% ->Stand-out brands included Modelo Especial, which grew 15% in Q1, and Pacifico, up 21%. ->Operating cash flow was up 6% to $758 million ->The beer business is still on track to grow sales by between 7% and 9% and boost profits at a slightly slower rate. ->$242 Constellation Brands (STZ), UBS PT-$270 - "At just under 21x NTM EPS estimates and with visibility to M/HSD organic revenue growth LT, we believe the risk/reward for STZ remains among the most attractive in our coverage universe." ->Arvinas, another clinical stage researcher. Arvinas is also making moves in the field of protein degradation – this is a relatively new area in clinical research, and offers a wide field for companies able to get in. Arvinas has established its own drug development platform, the proprietary PROTAC platform, for the engineering of proteolysis targeting chimeras. Over the past several years of operations, Arvinas has brought three drug candidates to the clinical study stage. ->Both of Arvinas’ leading candidates are designed to target a specific cancer. ARV-471, which was well-tolerated by patients in Phase 1 trials, is currently undergoing several clinical studies in the treatment of metastatic breast cancer. The company expects to release safety data from a Phase 1b combination trial, testing ARV-471 in conjunction with Palbociclib, during the second half of this year. Data from the Phase 2 VERITAC dose expansion trial is expected on a similar timeframe. Arvinas’ other leading drug candidate, ARV-110, branded as bavdegalutamide, is a potential treatment for metastatic castration-resistant prostate cancer (mCRPC). Upcoming catalysts this year include discussions with the FDA on the possibility of an accelerated approval pathway for the drug, to be held in 2Q, and a pivotal trial for mCRPC patients with the specific tumor mutations, AR T878/H875. This potential trial is planned for 2H22. In addition to these leading candidates, Arvinas has brought ARV-766 to the clinical stage. This drug candidate, like ARV-110, targets androgen receptor and is designed to treat mCRPC. The company plans to release Phase 1 data on dose escalation later this year and to initiate a Phase 2 expansion trial in the second half. In his coverage for Credit Suisse, Richard Law notes that this company has been a leader in the protein degradation field, witting: “ARVN is differentiated from other protein degrader companies by its leadership, deep history, and extensive experience in protein degradation. Its founders are pioneers of protein degradation, and ARVN has continued in their footsteps leading the field by being the first to develop an oral PROTAC, cross the blood -brain barrier (BBB ), achieve positive proof of concept (POC) in humans, and advance into Phase 2 study." Law goes on to note that ARV-471 has "potential to become the best-in-class estrogen receptor-targeting therapy," and describes ARV-110 as "a second pillar of value." With "many shots on goal and catalyst events in 2022," Law rates ARVN an Outperform (i.e. Buy) along with a $104 price target. Arvinas (ARVN),UBS PT- $151 - "High conviction call on targeted protein degradation technology, which we think could be the largest innovation in biopharma in the coming years, akin to the discovery of antibodies ($150B+ in current annual sales)." 1>ARVN Arvinas, Inc. $50.32 -4.48(-8.18%) 2>STZ Constellation Brands, Inc. $242.00
US gross domestic product -- the sum of goods and services produced -- is forecast to have risen an annualized 0.5% during the April-June period, according to the median estimate in a Bloomberg survey of economists. Following the 1.6% rate of decline in the prior quarter, the economy’s first-half performance would be the worst of the pandemic recovery. While inventories probably weighed heavily on the second-quarter results, the demand picture also darkened as consumer spending, business investment and housing may have all taken a step back. The advance GDP estimate will be released on Thursday, a day after Fed policy makers -- led by Chair Jerome Powell -- are expected to pull the trigger on another 75 basis-point increase in their benchmark interest rate as they try to arrest persistent inflation. Their challenge in tightening policy is to avoid overdoing it and nudging the economy into a downturn. A number of economists, in addition to the Atlanta Fed’s GDPNow estimate, forecast a second quarterly decline in GDP that would fit the technical definition of a recession. What Bloomberg Economics Says: “Powell faces a herculean task at the press conference: He’ll need to affirm the Fed’s commitment to its 2% inflation target while acknowledging the economy’s recent loss of momentum, as the 2Q GDP print (due the following day) will likely be negative. It’s harder to sound hawkish when economic activity is slowing than when it was robust.”